These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17580559)

  • 1. [Ibandronate].
    Babić-Naglic D; Grazio S
    Reumatizam; 2006; 53(2):72-6. PubMed ID: 17580559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Reginster JY
    Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
    Hashimoto J
    Clin Calcium; 2007 Jan; 17(1):11-7. PubMed ID: 17211088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibandronate: A Review in Japanese Patients with Osteoporosis.
    Keating GM
    Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ibandronate].
    Tobinai M
    Clin Calcium; 2011 Jan; 21(1):79-86. PubMed ID: 21187598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H; Sakai A; Ikeda S; Imanishi Y; Tsurukami H; Nakajo S; Miyakoshi N
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
    Ettinger MP; Felsenberg D; Harris ST; Wasnich R; Skag A; Hiltbrunner V; Wilson K; Schimmer RC; Miller PD
    J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.
    Hagino H; Ito M; Hashimoto J; Yamamoto M; Endo K; Katsumata K; Asao Y; Matsumoto R; Nakano T; Mizunuma H; Nakamura T
    J Bone Miner Metab; 2018 May; 36(3):336-343. PubMed ID: 28389932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
    Zaidi M; Epstein S; Harris ST; Kohles JD; Chesnut CH
    Ann N Y Acad Sci; 2007 Nov; 1117():273-82. PubMed ID: 18056047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment.
    Emkey R
    Womens Health (Lond); 2006 May; 2(3):341-9. PubMed ID: 19803906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ibandronate on bone quality: preclinical studies.
    Bauss F; Dempster DW
    Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.